Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons

American Journal of Pathology

Volumn 154, Issue 5, 1999, Pages 1423-1429

  Zhang, Jing ^a   Perry, George ^c   Smith, Mark A ^c   Robertson, David ^a,b   Olson, Sandra J ^a   Graham, Doyle G ^a   Montine, Thomas J ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYGUANINE; MITOCHONDRIAL DNA; NUCLEIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DORSAL RAPHE NUCLEUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEWY BODY; MALE; NERVE DEGENERATION; OCULOMOTOR NUCLEUS; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0032911488     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65396-5     Document Type: Article

References (40)

1. Lowe J, Graham L, Leigh PN: Disorders of movement and system degeneration. Greenfield's Neuropathology. Edited by Graham DI, Lantos PL. London, Arnold, 1997, pp 281-366
2. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD: Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989, 52: 1830-1836
3. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD: A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J Neurochem 1989, 53:692-697
4. Perry TL, Godin DV, Hansen S: Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982, 33:305-310
5. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y: Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996, 93:2696-2701
6. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B: A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997, 69:1326-1329
7. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B: Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997, 69:1196-1203
8. Fornstedt B, Brun A, Rosengren E, Carlsson A: The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm Park Dis Dement Sect 1989, 1:279-295
9. Cohen G: The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Trans (Suppl) 1983, 19:89-103
10. Graham DG: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978, 14:633-643
11. Li H, Dryhurst G: Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J Neurochem 1997, 69:1530-1541
12. Montine TJ, Underhill TM, Linney E, Graham DG: Fibroblasts that express aromatic amino acid decarboxylase have increased sensitivity to the synergistic cytotoxicity of L-dopa and manganese. Toxicol Appl Pharmacol 1994, 128:116-122
13. Hastings TG, Lewis DA, Zigmond MJ: Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 1996, 93:1956-1961
14. Ben SD, Zuk R, Glinka Y: Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995, 64:718-723
15. Montine TJ, Picklo MJ, Amarnath V, Whetsell WOJ, Graham DG: Neurotoxicity of endogenous cysteinylcatechols. Exp Neurol 1997, 148:26-33
16. Gabby M, Tauber M, Porat S, Simantov R: Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. Neuropharmacology 1996, 35:571-578
17. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P: Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995, 15:961-973
18. Clayton DA: Replication of animal mitochondrial DNA. Cell 1982, 28:693-705
19. Brown MD, Shoffner JM, Kim YL, Jun AS, Graham BH, Cabell MF, Gurley DS, Wallace DC: Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. Am J Med Genet 1996, 61:283-289
20. Ozawa T, Tanaka M, Ino H, Ohno K, Sano T, Wada Y, Yoneda M, Tanno Y, Miyatake T, Tanaka T, et al: Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease. Biochem Biophys Res Commun 1991, 176:938-946
21. Mayr-Wohlfart U, Rodel G, Henneberg A: Mitochondrial tRNA(GIn) and tRNA(Thr) gene variants in Parkinson's disease. Eur J Med Res 1997, 2:111-113
22. Ozawa T, Tanaka M, Ikebe S, Ohno K, Kondo T, Mizuno Y: Quantitative determination of deleted mitochondrial DNA relative to normal DNA in Parkinsonian striatum by a kinetic PCR analysis. Biochem Biophys Res Commun 1990, 172:483-489
23. Bandmann O, Sweeney MG, Daniel SE, Marsden CD, Wood NW: Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. J Neurol 1997, 244:262-265
24. Kosel S, Egensperger R, Schnopp NM, Graeber MB: The 'common deletion' is not increased in Parkinsonian substantia nigra as shown by competitive polymerase chain reaction. Mov Disord 1997, 12:639-645
25. Yin B, Whyatt RM, Perera FP, Randall MC, Cooper TB, Santella RM: Determination of 8-hydroxydeoxyguanosine by an immunoaffinity chromatography-monoclonal antibody-based ELISA. Free Radic Biol Med 1995, 18:1023-1032
26. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Smith MA: RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer disease. J Neurosci 1999, 19:1959-1964
27. Calne DB: Neurodegenerative Diseases. Philadelphia, WB Saunders, 1994, pp 545-582
28. Graham DG, Tiffany SM, Bell Jr WR, Gutknecht WF: Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978, 14:644-653
29. Ito S, Fujita K: Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical. Biochem Pharmacol 1982, 31:2887-2889
30. Misra HP, Fridovich I: The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972, 247:3170-3175
31. Fornstedt B, Rosengren E, Carlsson A: Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 1986, 25:451-454
32. Spencer JP, Jenner A, Aruoma OI, Evans PJ, Kaur H, Dexter DT, Jenner P, Lees AJ, Marsden DC, Halliwell B: Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett 1994, 353:246-250
33. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269
34. Wallace DC: Mitocriondrial genetics: a paradigm for aging and degenerative diseases? Science 1992, 256:628-632
35. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD: Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990, 55:2142-2145
36. Gu M, Gash MT, Cooper JM, Wenning GK, Daniel SE, Quinn NP, Marsden CD, Schapira AH: Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord 1997, 12:418-422
37. Li Q, Ling J, Liu WY: Partial restoration of inactivated ribosomes with sodium borohydride or amino acids. FEBS Lett 1995, 370:123-126
38. Colurso GJ, Kan RK, Anthony A: Microdensitometric measures of cytoplasmic RNA and total protein in pyramidal neurons of the insular cortex and midfrontal gyrus in patients with Alzheimer's disease. Cell Biochem Funct 1995, 13:287-292
39. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Koycu S, Ramdjielal RDJ, Salehi A, Martens GJM, Grosveld FG, Peter J, Burbach H, Hol EM: Frameshift mutants of β amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998, 279:242-247
40. Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD: Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998, 20:589-602